11:36 AM EDT, 09/17/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday its psoriasis drug candidate icotrokinra met both co-primary endpoints in the phase 3 Iconic-Advance 1 and 2 studies.

Icotrokinra showed "superior" skin clearance compared to placebo at week 16 and deucravacitinib at both weeks 16 and 24.

The treatment demonstrated similar adverse event rates when compared to placebo, with its adverse event rate being numerically lower than deucravacitinib through week 24.

Additionally, 52-week data from the phase 3 Iconic-Lead study showed sustained skin clearance and a favorable safety profile in both adults and adolescents, with no new safety signals identified.

The results are being presented at the 2025 European Academy of Dermatology and Venereology Congress, according to the company.

Price: 177.38, Change: +0.92, Percent Change: +0.52